Form 4: Twist Bioscience Director Melissa A. Starovasnik Reports Acquisition of Common Stock

Director Melissa A. Starovasnik reports acquisition of 4,472 shares of Twist Bioscience common stock and disposal of shares.

Summary

• On February 5, 2025, Melissa A. Starovasnik, a director of Twist Bioscience Corp, acquired 4,472 shares of common stock.
• The shares were acquired at a price of $0.
• Following the transaction, Starovasnik beneficially owns 21,627 shares of Twist Bioscience common stock.
• The acquisition was part of an annual equity award, which vests upon the earlier of the one-year anniversary of the grant date or the date of the first annual meeting of stockholders following the grant date, provided the director remains a service provider.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock acquisition by a director, which doesn't inherently indicate positive or negative sentiment.

Positives

• The acquisition of shares by a director may signal confidence in the company's future prospects.

Future Outlook

The annual equity award will vest upon the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the first annual meeting of stockholders following the date of grant, provided that the Non-Employee Director is a Service Provider on each vesting date.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for signals about management's confidence in the company.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence from a company director.

Key Dates